Related Experiment Video
Updated: Jul 9, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer
Y Loriot1, P Mordant1, D Dugue2
11] Gustave Roussy, Cancer Campus, Grand Paris, 114 rue Edouard Vaillant, Villejuif 94805, France [2] INSERM 1030 "radiosensitivity and human carcinogenesis", 114 rue Edouard Vaillant, Villejuif 94805, France [3] Faculty of Medicine, University of Paris-Sud, DHU TORINO, LABEX LERMIT, SIRIC Socrates, Le Kremlin-Bicêtre, France.
Abstract:
Radiotherapy has a critical role in the treatment of small-cell lung cancer (SCLC). The effectiveness of radiation in SCLC remains limited as resistance results from defects in apoptosis. In the current study, we investigated whether using the Bcl-2/Bcl-XL inhibitor S44563 can enhance radiosensitivity of SCLC cells in vitro and in vivo. In vitro studies confirmed that S44563 caused SCLC cells to acquire hallmarks of apoptosis. S44563 markedly enhanced the sensitivity of SCLC cells to radiation, as determined by a clonogenic assay. The combination of S44563 and cisplatin-based chemo-radiation showed a significant tumor growth delay and increased overall survival in mouse xenograft models. This positive interaction was greater when S44563 was given after the completion of the radiation, which might be explained by the radiation-induced overexpression of anti-apoptotic proteins secondary to activation of the NF-κB pathway. These data underline the possibility of combining IR and Bcl-2/Bcl-XL inhibition in the treatment of SCLC as they underscore the importance of administering conventional and targeted therapies in an optimal sequence.
Insights
This study shows that the Bcl-2/Bcl-XL inhibitor S44563 enhances radiosensitivity in small-cell lung cancer (SCLC) cells. Combining S44563 with chemo-radiation significantly delays tumor growth and improves survival in SCLC models.
Area of Science:
- Oncology
- Cancer Research
- Pharmacology
Background:
- Radiotherapy is crucial for small-cell lung cancer (SCLC) treatment, but resistance limits its effectiveness.
- Apoptosis defects contribute to radioresistance in SCLC.
- Targeting anti-apoptotic proteins offers a potential strategy to overcome resistance.
Purpose of the Study:
- To investigate if the Bcl-2/Bcl-XL inhibitor S44563 can enhance the radiosensitivity of SCLC cells.
- To evaluate the efficacy of combining S44563 with chemo-radiation in preclinical SCLC models.
Main Methods:
- In vitro studies assessed S44563's effect on SCLC cell apoptosis.
- Clonogenic assays determined radiosensitivity enhancement.
- Mouse xenograft models were used to evaluate tumor growth delay and survival with combination therapy.
Main Results:
- S44563 induced apoptosis hallmarks in SCLC cells.
- S44563 significantly increased SCLC cell sensitivity to radiation.
- Combination of S44563 and cisplatin-based chemo-radiation resulted in significant tumor growth delay and improved survival.
- Optimal sequencing of S44563 post-radiation showed enhanced efficacy, potentially due to NF-κB pathway modulation.
Conclusions:
- S44563 can enhance SCLC radiosensitivity by inducing apoptosis.
- Combining S44563 with chemo-radiation is a promising strategy for SCLC treatment.
- Optimal sequencing of conventional and targeted therapies is critical for maximizing treatment outcomes in SCLC.
